We are live on ! Find out more
ACXP icon

Acurx Pharmaceuticals
ACXP

23 hedge funds and large institutions have $4.24M invested in Acurx Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 7 increasing their positions, 1 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

600% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 1

222% more capital invested

Capital invested by funds: $1.32M → $4.24M (+$2.92M)

71% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 7

28% more funds holding

Funds holding: 18 → 23 (+5)

0.07% more ownership

Funds ownership: 0.34% → 0.4% (+0.07%)

65% less call options, than puts

Call options by funds: $284K | Put options by funds: $822K

Holders
23
Holders Change
+5
Holders Change %
+27.78%
% of All Funds
0.34%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
12
Increased
7
Reduced
1
Closed
7
Calls
$284K
Puts
$822K
Net Calls
-$538K
Net Calls Change
-$538K

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$1.08M
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$202K
3
BlackRock
BlackRock
New York
+$170K
4
Osaic Holdings
Osaic Holdings
Arizona
+$118K
5
State Street
State Street
Massachusetts
+$108K

Top Sellers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
-$750K
2
Renaissance Technologies
Renaissance Technologies
New York
-$28K
3
Millennium Management
Millennium Management
New York
-$20.8K
4
Citadel Advisors
Citadel Advisors
Florida
-$19.4K
5
TSS
Two Sigma Securities
New York
-$15.2K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$1.56M +$1.08M +14,257 +235%
PFS
2
Prospect Financial Services
New York
$977K +$963K +12,758 New
Geode Capital Management
3
Geode Capital Management
Massachusetts
$430K +$88.8K +1,177 +27%
BlackRock
4
BlackRock
New York
$242K +$170K +2,250 +248%
Osaic Holdings
5
Osaic Holdings
Arizona
$219K +$118K +1,563 +120%
Susquehanna International Group
6
Susquehanna International Group
Pennsylvania
$205K +$202K +2,678 New
Morgan Stanley
7
Morgan Stanley
New York
$124K +$65.7K +870 +116%
State Street
8
State Street
Massachusetts
$109K +$108K +1,428 New
TWC
9
TD Waterhouse Canada
Ontario, Canada
$73.5K – – –
Northern Trust
10
Northern Trust
Illinois
$65.7K +$64.8K +858 New
Citadel Advisors
11
Citadel Advisors
Florida
$52.5K -$19.4K -257 -27%
LPL Financial
12
LPL Financial
California
$52.4K +$51.6K +684 New
TAM
13
Tocqueville Asset Management
New York
$50.2K +$11.3K +150 +30%
SPC
14
Sigma Planning Corp
Michigan
$38.3K +$37.7K +500 New
SFA
15
Semmax Financial Advisors
North Carolina
$16.5K – – –
CPG
16
Cornerstone Planning Group
New Jersey
$12.8K +$12.6K +167 New
CG
17
Cutler Group
California
$8K +$8.68K +115 New
ASN
18
Advisory Services Network
Georgia
$4.53K +$4.45K +59 New
JP Morgan Chase
19
JP Morgan Chase
New York
$1.96K +$1.96K +26 New
GWSG
20
GPS Wealth Strategies Group
Colorado
$1.92K +$1.89K +25 New
Wells Fargo
21
Wells Fargo
California
$310 – – –
Bank of America
22
Bank of America
North Carolina
$54 +$75 +1 New
AC
23
Armistice Capital
New York
– -$750K -25,000 Closed
Renaissance Technologies
24
Renaissance Technologies
New York
– -$28K -940 Closed
Millennium Management
25
Millennium Management
New York
– -$20.8K -729 Closed
1
2

ACXP Hedge Fund Activity: Q4 2023 in Review

23 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Acurx Pharmaceuticals (ACXP) for Q4 2023, worth a combined $4.24M — up 222% from $1.32M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new ACXP positions and 7 closed out — a net gain of 5 holders — while 7 added to existing stakes and 1 trimmed.

The largest buyer was Vanguard Group, adding an estimated $1.08M. The largest seller was Armistice Capital, exiting entirely with an estimated $750K sold.

  • 23 institutional investors held Acurx Pharmaceuticals (ACXP) as of Q4 2023, up from 18 in Q3 2023.
  • Funds reported $4.24M of Acurx Pharmaceuticals stock for Q4 2023, up 222% quarter-over-quarter.
  • 12 funds opened new Acurx Pharmaceuticals positions in Q4 2023 and 7 closed out, a net change of +5 holders.
  • The largest Acurx Pharmaceuticals buyer in Q4 2023 was Vanguard Group, an estimated $1.08M added.
  • The largest Acurx Pharmaceuticals seller in Q4 2023 was Armistice Capital, an estimated $750K sold.

Based on aggregated 13F filings for Q4 2023.